ScreenerHero

EPRX Eupraxia Pharmaceuticals Inc.

NAS · US · Healthcare · Biotechnology · eupraxiapharma.com
7.570USD-2.70%Mkt Cap: 500.18M $P/E: —

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug de…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap500.18M USD
Enterprise Value406.22M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-38.58M USD
Revenue/Share—
Last Price7.570 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees49
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.46
PEG—
EV/EBITDA-7.14
EV/Revenue—
P/S—
P/B4.98
EPS (TTM)-1.02
EPS (Forward)-1.04
52W Range
5.25057% of range9.320
52W High9.320 USD
52W Low5.250 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-47.02%
ROA-44.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.55M USD
CapEx (TTM)588.95K USD
FCF Margin—
FCF Yield-3.78%
Net Debt-131.82M USD
Net Debt/EBITDA2.32
Balance Sheet
Debt/Equity0.00
Current Ratio16.00
Quick Ratio15.71
Book Value/Sh1.55 USD
Cash/Share2.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.35 USD
Upside (mean)+116.0%
Target Range11.00 USD – 25.00 USD
11.00+116.0% to mean25.00
# Analysts10
Ownership
Shares Out.66.07M
Float55.67M
Insiders12.11%
Institutions43.34%
Short Interest
Short Ratio14.4d
Short % Out.11.48%
Shares Short7.58M
Short (prev mo.)6.34M
Technical
SMA 507.356 (+2.9%)
SMA 2007.338 (+3.2%)
Beta1.22
S&P 52W Chg16.45%
Avg Vol (30d)853.76K
Avg Vol (10d)1.26M
Technical Indicators
RSI (14)47.3
MACD0.0833
MACD Signal0.2181
MACD Hist.-0.1348
BB Upper8.960 USD
BB Middle8.117 USD
BB Lower7.273 USD
BB Width20.77%
ATR (14)0.5586 USD
Vol Ratio (20d)0.71x